This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Dynavax May Seek Quick Re-File of HepB Vax Following FDA Rejection

BERKELEY, Calif. ( TheStreet) -- The U.S. Food and Drug Administration rejected Dynavax's (DVAX - Get Report) hepatitis B vaccine Heplisav, citing the need for additional safety data in healthy adults.

Dynavax shares fell 37% to $1.88 in Monday's pre-market session because that's what happens to companies who fail to get their first product to market on time. The stock closed Friday at $2.97

How long Dynavax will need to wait before re-filing Heplisav isn't clear but the company may not be delayed too long if it decides to seek approval first in a sicker patient population. "The Agency indicated its willingness to continue discussions regarding a more restricted use of Heplisav," Dynavax said in its Monday statement.

That restricted patient population could be people with chronic kidney disease. Dynavax was already planning to submit additional Heplisav data on this patient population as a post-approval supplement.

Dynavax might be able to re-file Heplisav in chronic kidney disease patients by the middle of this year, with approval and commercial launch in the middle of 2014, said Jefferies analyst Thomas Wei in a research note issued last Thursday. A broader label for Heplisav could be approved in 2015, he added.

Dynavax plans to meet with FDA within six weeks to discuss options.

In rejected Heplisav, FDA concurred with the recommendation of an advisory panel, which voted against the vaccine because of concerns about the lack of safety data in a broad population of healthy adults aged 18-70.

The FDA's rejection letter also asked Dynavax to provide additional information related to Heplisav's manufacturing.

"We had the chance to speak with the company, and it noted that there are essentially two options at the moment 1) run an additional safety study in patients aged 18-70 years, or 2) move forward with a more restrictive label (CKD or >40 years of age)," writes J.P. Morgan analyst Geoff Meacham in a research note issued Monday morning. "Of note, the request for manufacturing data comes as somewhat of a surprise, but the company is confident it can provide the requested information."

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DVAX $22.70 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%
GOOG $548.34 0.00%
TSLA $185.00 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs